New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 19, 2013
05:55 EDTARTC, ARTC, ARTC, ARTC, ARTC, MDT, MDT, MDT, MDT, MDT, MGLN, MGLN, MGLN, MGLN, MGLN, MAKO, MAKO, MAKO, MAKO, MAKO, KYO, KYO, KYO, KYO, KYO, ECL, ECL, ECL, ECL, ECL, COV, COV, COV, COV, COV, CYH, CYH, CYH, CYH, CYH, CFN, CFN, CFN, CFN, CFN, BMTI, BMTI, BMTI, BMTI, BMTI, BAX, BAX, BAX, BAX, BAX, AXGN, AXGN, AXGN, AXGN, AXGN, AUXL, AUXL, AUXL, AUXL, AUXL, OSIR, OSIR, OSIR, OSIR, OSIRAmerican Academy of Orthopaedic Surgeons to host annual meeting
AAOS 2013 Annual Meeting is being held in Chicago on March 19-23.
News For ARTC;AUXL;AXGN;BAX;BMTI;CFN;CYH;COV;ECL;KYO;MAKO;MGLN;MDT;OSIR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 17, 2015
16:36 EDTBAXBaxter says results of Phase III clinical trial of BAX 111 met primary endpoint
Subscribe for More Information
08:33 EDTOSIROsiris management to meet with Brean Capital
Subscribe for More Information
07:10 EDTMDTMedtronic's Solitaire improved neurological outcomes in stroke patients in trial
Subscribe for More Information
April 16, 2015
19:46 EDTECLEcolab to acquire Travelers North Tower in St. Paul, MN, terms not disclosed
Ecolab (ECL) has signed a purchase agreement to acquire the 17-story North Tower from Travelers (TRV) in downtown St. Paul, MN. The transaction is expected to close in Q3, and by the end of 2018, Ecolab will relocate all associates from the three buildings that comprise its world headquarters in downtown St. Paul to the North Tower. Financial terms of the agreement are not being disclosed.
09:03 EDTBAXBaxter submits application to Japan's MHLW for approval of BAX 855
Baxter International (BAX) announced that the company has submitted a new drug application to Japan’s Ministry of Health, Labour and Welfare for the approval of BAX 855, an investigational, extended half-life recombinant factor VIII treatment based on ADVATE for patients over 12 years of age with hemophilia A. The submission follows the filing to the United States Food and Drug Administration in late 2014 and is based on positive results from a prospective, global, Phase 3 study of 137 previously treated patients. The results, presented during the European Association for Haemophilia and Allied Disorders meeting in February 2015, demonstrated that BAX 855 met its primary endpoint in the control and prevention of bleeding episodes and routine prophylaxis for patients who were 12 years or older. Baxter continues to advance a continuation study for patients who completed the pivotal trial and a Phase 3 study among previously treated patients under the age of 12 with severe hemophilia A. Once the pediatric study has been completed, the company expects to file for marketing authorization with the European Medicines Agency in 2016 and intends to seek post-approval label expansion in the U.S. for previously-untreated pediatric patients. BAX 855 is based on ADVATE, a full-length FVIII molecule with more than 12 years of real-world experience. Through a collaboration with Nektar Therapeutics (NKTR), BAX 855 leverages proprietary pegylation technology designed to extend the duration of activity of the protein in the body. This proprietary technology has been used for over 10 years in a number of approved medicines that treat chronic or serious conditions.
April 15, 2015
08:40 EDTCYHHospital stocks rise in pre-market after HCA boosts 2015 guidance
Subscribe for More Information
08:13 EDTBAXCoherus, Baxter announce amendment to etanercept biosimilar agreement
Coherus BioSciences (CHRS) and Baxter International (BAX) announced that they have amended certain financial terms of their collaboration agreement established in August 2013 regarding the development and commercialization of CHS-0214, an etanercept biosimilar product candidate, for Europe, Canada, Brazil, and certain other markets. Under the terms of the amended agreement, certain existing milestones and funding obligations have been revised, and the collaboration has been expanded to include select pre-commercialization activities. In aggregate, the revised milestone payments may exceed the previous Baxter funding obligations by approximately $12M. Additionally, Baxter has agreed to purchase Coherus common stock in a private placement transaction. All other contractual provisions remain materially unchanged.
April 14, 2015
11:04 EDTMDTMedtronic to develop stent graft system under patent agreement with Sanford
Subscribe for More Information
09:16 EDTMDTMedtronic announces CE Mark for Micra TPS
Subscribe for More Information
07:38 EDTBAXBaxter removed from the short-term buy list at Deutsche Bank
Subscribe for More Information
April 13, 2015
17:13 EDTMDTIBM Medtronic to partner to improve diabetes care
IBM (IBM) and Medtronic (MDT) announced that they will work together to combine powerful analytics and cognitive computing with diabetes medical devices and health data to develop a new generation of personalized diabetes management solutions. People using Medtronic diabetes solutions could benefit from new solutions developed in collaboration with IBM's newly-formed Watson Health unit.
17:10 EDTMDTIBM establishes a Watson Health Cloud
Subscribe for More Information
April 10, 2015
15:37 EDTMDTMedtronic looking to sell medical supplies business, dealReporter says
Subscribe for More Information
08:51 EDTBAXBaxter initiates voluntary recall of select lots of IV solutions
Subscribe for More Information
07:35 EDTMDTExpert comments bullish for Edwards, Medtronic, says RBC Capital
Subscribe for More Information
April 9, 2015
08:03 EDTOSIROsiris names Alla Danilkovitch as Chief Scientific Officer
Subscribe for More Information
April 8, 2015
07:24 EDTMDTNeurotechnology Industry Organization to hold a conference
Subscribe for More Information
April 7, 2015
10:23 EDTMGLNMedicare Advantage 2016 rates set above expectations
The U.S. yesterday announced higher than expected 2016 Medicare Advantage reimbursement rates. The news is seen as benefiting managed care companies with large exposure to the Medicare Advantage program. WHAT'S NEW: The Centers for Medicare and Medicaid Services, or CMS, yesterday afternoon announced that Medicare Advantage reimbursement rates would rise 1.25% in 2016 from 2015 levels. In February, CMS proposed a 0.95% reduction in Medicare Advantage reimbursement rates for 2016. This year, reimbursement rates have fallen 4%. WHAT'S NOTABLE: Humana (HUM) said this morning in a regulatory filing that based on its review of the Final Rate Notice, the company expects an average Medicare Advantage funding increase for its business of approximately 0.8% from CMS for 2016, versus a funding decline of 1.25%-1.75% previously expected based on the Advance Notice. Humana’s estimated year-over-year funding increase as it affects the company is projected to be less than the CMS estimate for the MA program primarily due to Humana’s view of the projected impact associated with CMS’ 2016 adjustment to the risk model calculation, the company explained. ANALYST REACTION: In a note to investors earlier today, Deutsche Bank analyst Scott Fidel wrote that this is the first time in seven years that CMS has implemented an increase in Medicare Advantage rates. However, noting that CMS said it had raised its estimates for Medicare costs, Fidel added that this forecast tempered the positive outlook created by the reimbursement increase. The analyst kept Buy ratings on the following stocks in the sector: Aetna (AET), Anthem (ANTM), Cigna (CI), Magellan Health (MGLN), and UnitedHealth (UNH). Stifel analysts said that the results were modestly better than expected, except for the agency's decision not to make a Star rating adjustment for plans with certain higher acuity populations. The firm thinks that more diversified managed care companies with Medicare Advantage products could be boosted by CMS' decision, identifying Aetna, Humana, and UnitedHealth as being among the companies in that category. PRICE ACTION: In early trading, Aetna was little changed at $107.40, Anthem was flat near $155 per share, Cigna slipped 0.4% to $131.34, Magellan was flat at $71, UnitedHealth added 0.5% to $118.31 and Humana gained fractionally to $178.54.
April 6, 2015
13:09 EDTMDTMedtronic signs development deal with Israeli start-up, Globes says
Subscribe for More Information
07:57 EDTMGLNLeerink healthcare services analyst holds analyst/industry conference call
Healthcare Services Analyst Gupte discusses the leverage Anthem likely has in its Pharmacy Benefit Manager (PBM) contract with Express Scripts and how it changes after the Catamaran-Optum Rx deal, the synergy potential for the deal between Catamaran and Optum Rx and the likelihood of Cigna-HS remaining with the newly merged Optum Rx-CTRX on an Analyst/Industry conference call to be held on April 6 at 2 pm.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use